Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
News and updates for Enanta Pharmaceuticals, Inc. (ENTA) focus on its progress as a clinical-stage biotechnology company developing small molecule drugs for viral infections and immunological diseases. Company press releases frequently highlight clinical data, regulatory designations, pipeline milestones, financial results, capital raises, and intellectual property developments.
Investors following ENTA news can expect detailed coverage of RSV clinical programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an oral L-protein inhibitor. Enanta regularly reports Phase 2 and Phase 2b trial readouts in high-risk adult and pediatric RSV populations, human viral challenge data, and analyses of symptom resolution, viral load reductions, and safety outcomes. Updates also cover Phase 3-enabling activities and interactions with the U.S. Food and Drug Administration on trial design and registration pathways.
News items also track Enanta’s immunology pipeline, such as the nomination of EPS-3903, an oral STAT6 inhibitor for atopic dermatitis and other type 2 immune-driven diseases, and the selection of EDP-978, an oral KIT inhibitor for chronic spontaneous urticaria and other mast cell–driven conditions. Announcements describe preclinical potency, selectivity, and planned IND filings and early clinical timelines, as well as the expansion of discovery programs targeting MRGPRX2.
On the corporate side, ENTA news includes quarterly and annual financial results, commentary on royalty revenue from AbbVie’s HCV regimen MAVYRET/MAVIRET, and disclosures about cash runway expectations. Coverage also includes public equity offerings, underwritten offering terms, and use of proceeds, along with patent litigation developments, such as Enanta’s infringement action in the Unified Patent Court related to its coronavirus protease inhibitor patent. For ongoing insight into ENTA’s clinical, financial, and legal developments, this news feed aggregates the company’s latest official announcements.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced on May 18, 2021, that CEO Jay R. Luly, Ph.D., will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at 1:20 p.m. ET. Investors can access a live webcast of the event on Enanta’s website, with a replay available for approximately 90 days afterward.
Enanta focuses on developing small molecule drugs for viral infections and liver diseases. Their clinical candidates target RSV, HBV, and NASH, with funding primarily from royalties on HCV products developed in collaboration with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced promising results from its Phase 1b study of EDP-514 in chronic hepatitis B virus (HBV) patients. The drug demonstrated safety and tolerability while achieving a mean reduction of HBV RNA of 1 log after 28 days, compared to 0.3 log in the placebo group. The study included 24 patients treated with nucleoside reverse transcriptase inhibitors. EDP-514 showed favorable pharmacokinetics for once-daily dosing, paving the way for combination therapies aimed at achieving functional cures for chronic HBV infection.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q2 2021 results, with total revenue of $20.1 million, down from $27.6 million year-over-year, impacted by the pandemic's effects on HCV sales. R&D expenses rose to $41.5 million from $32.6 million, while G&A expenses increased to $8.3 million. The net loss widened to $22.0 million, or $1.09 per diluted share, compared to $6.0 million, or $0.30 per share, in Q2 2020. Enanta remains well-capitalized with $400.4 million in cash, supporting its ongoing clinical programs in HBV, RSV, and NASH.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced it plans to report its financial results for the fiscal second quarter ending March 31, 2021, after U.S. market close on May 6, 2021. Following the announcement, management will host a conference call at 4:30 p.m. ET to discuss the results and provide updates on the company's R&D pipeline, focusing on treatments for viral infections and liver diseases. Key areas of development include candidates for respiratory syncytial virus, hepatitis B virus, and non-alcoholic steatohepatitis. Enanta's activities are primarily funded through royalties from HCV products developed with AbbVie.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that CEO Jay R. Luly will present at three virtual investor conferences. Key presentations include:
- H.C. Wainwright & Co. Global Life Sciences Conference on March 9, 2021
- 33rd Annual Roth Conference on March 15, 2021, discussing COVID-19 therapies
- Oppenheimer & Co. Healthcare Conference on March 16, 2021
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that Jay R. Luly, Ph.D., its CEO, will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 8:40 am ET. The presentation will be accessible via live webcast on Enanta's website, with a replay available for 90 days. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with clinical candidates for respiratory syncytial virus, hepatitis B, and non-alcoholic steatohepatitis. Their research is funded by royalties from hepatitis C products developed with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q1 2021 results, highlighting a revenue decline to $31.7 million from $52.6 million due to lower HCV sales. R&D expenses increased to $36.7 million, and net loss expanded to $8.3 million, or $0.41 per share. Key pipeline advancements include ongoing Phase 1b trials for HBV drugs EDP-514 and EDP-721, and the Phase 2b study for RSV drug EDP-938. The company expects preliminary data from its HBV trials in Q2 2021 and aims to identify two clinical candidates in respiratory virology this year.
Enanta Pharmaceuticals (NASDAQ:ENTA) will report its fiscal Q1 results on February 8, 2021, after market close. The company's management will host a conference call at 4:30 p.m. ET to discuss the results and provide updates on its R&D pipeline, targeting viral infections and liver diseases. Enanta’s research focuses on diseases like respiratory syncytial virus, hepatitis B, and non-alcoholic steatohepatitis, with funding derived from royalties from its collaboration with AbbVie for hepatitis C virus treatments.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced the appointment of Brendan Luu as Senior Vice President of Business Development, enhancing its leadership team. With over 20 years of experience in the pharmaceutical sector, Luu previously held significant roles at Merck KGaA, focusing on business development strategies. This transition comes as Enanta prepares for a catalyst-rich year, particularly in advancing its pipeline targeting viral infections and liver diseases, including promising candidates for RSV and hepatitis B.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced a pipeline update at the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2021. CEO Jay R. Luly highlighted the launch of EDP-721, a promising oral hepatitis B candidate, and advancements in respiratory syncytial virus (RSV) programs, including an RSV-L inhibitor initiative. Five clinical trials were initiated in 2020, with key data expected from ongoing studies in NASH and HBV in 2021. Enanta aims to achieve a functional cure for HBV and address significant respiratory diseases.